The Latest Breaking News from Needham

Needham Maintains Buy Rating for Calix: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Calix (NYSE:CALX) and lower its price target from $73.00 to $60.00. Shares of Calix are trading up 3.28% over the last 24 hours, at $39.34 per share. A move to $60.00 would account for a 52.52% increase from the current share…

Benzinga · Apr 27, 2022

Here's Why Analysts Were Impressed Post Cadence Design Systems' Q1 Performance

Cadence Design Systems, Inc (NASDAQ:CDNS) impressed analysts post Q1 beat. Baird reiterated Outperform rating on Cadence, adjudging it as a top idea.  All business groups saw strength, with recurring revenues increasing 19% YoY (led by Digital and System Design) and upfront revenues rising 49% YoY.  FY22 outlook raised given 1Q strength, upside in 2Q,…

Benzinga · Apr 26, 2022

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Benzinga · Apr 21, 2022

Here's What Made Needham Bullish On Nvidia, AMD Versus Others In Semiconductor Space

Needham shifted its focus on NVIDIA Corp (NASDAQ: NVDA) and Advanced Micro Devices Inc (NASDAQ: AMD).

Benzinga · Apr 18, 2022

Deutsche Bank Sees Netflix In Line With 2.5M Subscriber Guidance

Deutsche Bank analyst Bryan Kraft maintained his Q1 global subscriber estimate, in line with Netflix Inc's (NASDAQ:NFLX) 2.5 million guidance amid cutthroat competition and Covid resurgence. He saw net adds inching closer to 3.5 million when not accounting for Russia's 1 million base adjustment.  Also Read: Needham Sees Netflix Losing Out To Amazon, Disney, Apple and…

Benzinga · Apr 18, 2022

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21. Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is…

Benzinga · Apr 13, 2022

Bitcoin Miami 2022 Showed An Institutional Shift, Says Analyst

Following the conclusion of the 2022 Bitcoin (CRYPTO: BTC) conference held in Miami, Florida, an analyst at Needham shared his key takeaways.

Benzinga · Apr 13, 2022

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

Benzinga · Apr 8, 2022

Read Why Needham Is Bullish On This Pet Retailer

Needham analyst Anna Andreeva gave Petco Health And Wellness Co Inc (NASDAQ:WOOF) a Buy rating with a price target of $30.00 (45% upside). Andreeva notes Petco is becoming an omni-channel powerhouse after revamping its digital capabilities under CEO Ron Coughlin. The analyst thinks that the company’s bundled offerings model has a significant advantage over digital-only players. Petco…

Benzinga · Apr 8, 2022

Needham Initiates Alcon Citing 'Visible Path to Sustainable Double-Digit EPS Growth'

Needham is initiating coverage on Alcon AG (NYSE: ALC) with a Buy rating and 

Benzinga · Apr 8, 2022